{"filing":{"accession_number":"0001193125-26-269387","cik":"0001817713","ticker":"JANX","company_name":"Janux Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"janx-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526269387/janx-20260611.htm"},"events":[{"id":10790,"run_id":9467,"accession_number":"0001193125-26-269387","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a Form 8-K Item 5.07 disclosure of shareholder voting results from Janux Therapeutics' June 11, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for three proposals: election of two Class II directors (Natasha Hernday and Eric Dobmeier), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, and the disclosure is material as it documents the outcome of the annual shareholder meeting and confirms the election of directors and auditor selection.","company_name":"Janux Therapeutics, Inc.","ticker":"JANX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7190,"accession_number":"0001193125-26-269387","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a Form 8-K Item 5.07 disclosure of shareholder voting results from Janux Therapeutics' June 11, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for three proposals: election of two Class II directors (Natasha Hernday and Eric Dobmeier), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, and the disclosure is material as it documents the outcome of the annual shareholder meeting and confirms the election of directors and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:49.575171+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7190,"accession_number":"0001193125-26-269387","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a Form 8-K Item 5.07 disclosure of shareholder voting results from Janux Therapeutics' June 11, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for three proposals: election of two Class II directors (Natasha Hernday and Eric Dobmeier), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, and the disclosure is material as it documents the outcome of the annual shareholder meeting and confirms the election of directors and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:17:49.575171+00:00","company_name":"Janux Therapeutics, Inc.","ticker":"JANX","filing_date":"2026-06-12"}]}